Feed ELOX
EL

Eloxx Pharmaceuticals, Inc. ELOX NASDAQ · Healthcare · United States

$10.69 +0.38% +$0.04

Market cap
$36.6M
Enterprise value
$32.8M
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
59.0%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
-9.95
Free float
9.0%

About the company

Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Sumit Aggarwal

Employees

10

Headquarters

Watertown

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: It earns 59 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $56.3M against $11.8M.
  • What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
  • What to watch: For every 100 USD of bills due within a year it has 31 USD of short-term assets.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy